Newracle Genetics
Neuraclegen is dedicated to realizing the human dream of a healthy life through science. The company focuses on developing gene therapies for various diseases, including eye diseases, neurological disorders, and degenerative diseases, utilizing advanced vector engineering technologies. They aim to extend human health span by creating innovative gene-based treatments and establishing a reliable platform for large-scale production of gene therapy vectors.
Industries
Nr. of Employees
small (1-50)
Newracle Genetics
145 Anam-ro, Seongbuk-gu, Seoul, Korea, Korea University Natural Science Campus, 4th Floor
Products
AAV-based gene therapy candidate for neovascular (wet) age-related macular degeneration
An AAV-delivered therapeutic designed for treatment of wet age-related macular degeneration intended to provide durable intraocular expression of a therapeutic protein after a single administration.
AAV-based gene therapy candidate for neuropathic pain
A gene therapy program targeting neuropathic pain syndromes using AAV-mediated delivery of therapeutic transgenes to modulate pain signaling pathways.
AAV-based gene therapy candidate for Alzheimer's disease
AAV-delivered therapeutic aimed at reducing accumulation of toxic proteins and supporting neuronal and vascular repair processes to treat Alzheimer's disease.
AAV-based gene therapy candidate for amyotrophic lateral sclerosis (ALS)
A gene therapy program intended to address motor neuron degeneration in ALS using AAV-mediated delivery of therapeutic transgenes to slow disease progression.
Gene therapy constructs expressing neutralizing antibody fragments for CNS repair
A program to deliver genes encoding neutralizing antibody fragments (single-chain formats) against secreted peptides that drive reactive gliosis and glial scar formation, delivered via AAV for sustained local expression.
AAV-based gene therapy candidate for neovascular (wet) age-related macular degeneration
An AAV-delivered therapeutic designed for treatment of wet age-related macular degeneration intended to provide durable intraocular expression of a therapeutic protein after a single administration.
AAV-based gene therapy candidate for neuropathic pain
A gene therapy program targeting neuropathic pain syndromes using AAV-mediated delivery of therapeutic transgenes to modulate pain signaling pathways.
AAV-based gene therapy candidate for Alzheimer's disease
AAV-delivered therapeutic aimed at reducing accumulation of toxic proteins and supporting neuronal and vascular repair processes to treat Alzheimer's disease.
AAV-based gene therapy candidate for amyotrophic lateral sclerosis (ALS)
A gene therapy program intended to address motor neuron degeneration in ALS using AAV-mediated delivery of therapeutic transgenes to slow disease progression.
Gene therapy constructs expressing neutralizing antibody fragments for CNS repair
A program to deliver genes encoding neutralizing antibody fragments (single-chain formats) against secreted peptides that drive reactive gliosis and glial scar formation, delivered via AAV for sustained local expression.
Services
Co-development and licensing collaborations with pharmaceutical and biotech companies to advance gene therapy candidates from discovery through clinical development.
Development and optimization of AAV upstream (culture/production) and downstream (purification) processes with an emphasis on scalability for clinical and commercial supply.
Preclinical study design and execution in CNS injury and neurodegenerative disease models to evaluate therapeutic constructs, histological endpoints, and functional outcomes.
Support for IND preparation, regulatory interactions and early-phase clinical trial execution, including participation in regulatory designation processes intended to accelerate development.
Co-development and licensing collaborations with pharmaceutical and biotech companies to advance gene therapy candidates from discovery through clinical development.
Development and optimization of AAV upstream (culture/production) and downstream (purification) processes with an emphasis on scalability for clinical and commercial supply.
Preclinical study design and execution in CNS injury and neurodegenerative disease models to evaluate therapeutic constructs, histological endpoints, and functional outcomes.
Support for IND preparation, regulatory interactions and early-phase clinical trial execution, including participation in regulatory designation processes intended to accelerate development.
Expertise Areas
- AAV vector engineering
- AAV manufacturing and CMC process development
- Gene expression optimization for gene therapy
- Preclinical CNS disease and injury models
Key Technologies
- Adeno-associated virus (AAV) vector engineering
- Scalable AAV production and cell-culture processes
- AAV downstream purification methods
- Promoter and intron sequence engineering for enhanced expression
News & Updates
The gene therapy NG101 for wet AMD has been selected for clinical support by the National New Drug Development Project, with ongoing clinical trials and plans for large-scale licensing.
Domestic biotech companies are developing next-generation treatments with semi-permanent effects, aiming for KOSDAQ listing.
NG101 has been selected for clinical support by the government, with ongoing clinical trials and collaborations with Ilyang Pharmaceutical.
Industry experts discuss the importance of field-connected strategies in drug development.
Domestic biotech companies are working on treatments with long-lasting effects, aiming for future market expansion.
The gene therapy NG101 for wet AMD has been selected for clinical support by the government, facilitating clinical trials and potential market entry.
The gene therapy NG101 for wet AMD has been selected for clinical support by the National New Drug Development Project, with ongoing clinical trials and plans for large-scale licensing.
Domestic biotech companies are developing next-generation treatments with semi-permanent effects, aiming for KOSDAQ listing.
NG101 has been selected for clinical support by the government, with ongoing clinical trials and collaborations with Ilyang Pharmaceutical.
Industry experts discuss the importance of field-connected strategies in drug development.
Domestic biotech companies are working on treatments with long-lasting effects, aiming for future market expansion.
The gene therapy NG101 for wet AMD has been selected for clinical support by the government, facilitating clinical trials and potential market entry.